Detail akcie Intl Stem Cell online

Business Summary: International Stem Cell Corporation is a clinical-stage biotechnology company that is focused on therapeutic and biomedical product development. The Company is primarily a research and development company for the therapeutic market, which has focused on advancing potential clinical applications of human parthenogenetic stem cells (hpSCs) for the treatment of various diseases of the central nervous system and liver diseases. The Company's products are based on human cell culture and types of pluripotent stem cells and hpSCs. The Company's subsidiaries include Lifeline Cell Technology, LLC (LCT), which develops, manufactures and commercializes primary human cell research products for the biomedical market; Lifeline Skin Care, Inc. (LSC), which develops, manufactures and markets a category of anti-aging skin care products for anti-aging market, and Cyto Therapeutics Pty. Ltd. (Cyto Therapeutics) performs research and development (R&D) for the therapeutic market.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, International Stem Cell Corp revenues increased 17% to $9.1M. Net loss increased 60% to $209K. Revenues reflect Biomedical market segment increase of 21% to $8.3M, United States segment increase of 18% to $7.7M, Asia segment increase of 23% to $890K, Europe segment increase of 3% to $407K. Higher net loss reflects Anti-aging cosmetic market segment loss increase of 16% to $602K.